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Objectives. Previous literature has suggested an association between AAA and the presence of elevated plasma homocys-
teine levels (HCY). Homocysteine can stimulate elastolysis in the arterial media via activation of elastase and matrix
metalloproteinases. No evidence in the literature exists correlating aneurysm expansion and HCY. The study objective
is to identify whether the rate of AAA expansion is related to HCY.
Methods. 108 patients undergoing surveillance for AAA were identified at our vascular surgical unit. AAA size and
growth rate were assessed by serial ultrasongraphic measurements. Fasting total HCY levels were measured using fluores-
cence polarisation immunoassays. Demographic details and atherosclerotic risk factors were noted all AAA patients. A
multivariate analysis was performed for growth rate vs. HCY, hypertension and hypercholesterolaemia. The correlation
between AAA growth rate, AAA size and HCY levels were calculated.
Results. 60% of patients with AAA had some degree of hyperhomocysteinaemia (>15 mmol/l). Multivariate analysis
showed HCY to be the only significant factor affecting AAA growth rate. A positive correlation was demonstrated between
HCY levels and AAA growth rate using a linear regression model (R¼ 0.28, p¼ 0.003). Median growth rate among
patients with hyperHCY was double that of patients with normal HCY (0.5 mm/month vs. 0.25 mm/month, p¼ 0.003).
A growth rate of >10 mm/year was seen in 25% of hyper HCY patients and in only 2% of patients with normal HCY.
In addition patients with hyper HCY and larger AAAs (>4 cm) had a growth rate twice as fast as patients with hyper
HCY and AAAs <4 cm.
Conclusions. A correlation between HCY and growth rate exists, although this is weak due to the multifactorial aetiology
of AAAs. HyperHCY patients have faster expansion rates than patients with normal HCY, with significant numbers
demonstrating rapid expansion (>10 mm/year) and therefore an increased risk of rupture.
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Homocysteine is a sulphur containing amino acid that
is formed during the metabolism of the essential
amino-acid methionine1 (Fig. 1). High levels of homo-
cysteine (Hcy) in the blood (hyperhomocysteinaemia)
have been associated with increased risks of develop-
ing vascular occlusive disease.2 Plasma Hcy is now
regarded as an independent risk factor for atheroscle-
rotic disease, with raised levels present in significant
numbers of patients with peripheral, cerebrovascular
and coronary heart disease (CHD).3e6 High values
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lar intervention,7 and more rapid progression of CHD
and peripheral vascular disease.8e10
Mild hyperhomocysteinaemia (Table 1) is present
in 5e7% of the general population, due to either
inherited or acquired dietary deficiencies of vitamin
B12, and folic acid (co-enzymes which regulate
pathways catalysed by methylenetetrahydrofolate
reductase) or vitamin B6 (a cofactor for cystathionine
b-synthase).11,12 Other causes of acquired elevated
homocysteine include, renal failure, malignancy,
hypothyroidism and use of folate and vitamin B6
antagonists.11
The prevalence of raised homocysteine levels in
vascular patients has been demonstrated in a number
of recent studies, with up to 50% of patients with aor-
tic aneurysms having raised homocysteine levels but
data is still relatively limited.13e15 The literature
remains conflicting with respect to the possible rolerved.
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ing an association between Hcy levels and larger
aneurysms, while others have found no connection
between Hcy levels and AAA expansion.16e18
The aim of this study is to test the hypothesis that
the level of plasma Hcy predicts the rate of expansion
of AAAs.
Methods
The study was approved by the local research ethics
committee, and informed consent was obtained from
all participants. All patients with an AAA under
surveillance from January 2004 to January 2006 at
St James’ University Hospital were identified. Ultra-
sound scan reports of the aneurysms were collected,
as were the patient demographics and risk factors. In-
clusion criteria included the availability of at least two
consecutive ultrasound scans, availability of clinical
notes, and the adequate sampling of homocysteine
levels as described.
Homocysteine levels were measured prospectively
at the time of diagnosis of the AAA. Patients were
fasted for 6 hours prior to venesection, and samples
were concurrently taken for cholesterol, CRP and
creatinine analysis. Homocysteine samples were col-
lected in Vacutainer tubes containing ethylenedi-
amine tetraacetic acid (EDTA) and the plasma was
separated by centrifuge within 30 minutes of venesec-
tion. Samples were stored at 80 C. Total plasma
homocysteine was the measured using a fluorescence
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Fig. 1. Brief summary of homocysteine metabolism.
Table 1. Demonstrates a classification commonly used for homo-
cysteine values
Degree of
hyperhomocysteinemia
Blood level total
Hcy (mmmol/l)
Normal 5e14
Moderate (Mild) 15e30
Intermediate (Moderate) 31e100
Severe >100Eur J Vasc Endovasc Surg Vol 33, April 2007polarisation immunoassay on an Abbott IMX
analyser.
Statistical Methods
Data was collected using Microsoft Excel version X,
GraphPad Prism version 4.00 for Mac OSX was used
to analyse statistics.
Patients were divided into two groups, those with
hyperhomocysteinaemia (Hcy 15 mmol/l) and those
within the normal range (Table 1). As the distribution
of the patients age and Hcy levels was skewed toward
higher values, analysis was based on medians and
interquartile ranges. Subsequent analysis of the data
began with calculation of the change in size of the
infrarenal aortic diameter and the time in months
between the scan performed at the time of the Hcy as-
say and latest scan for all patients who attended at
least 2 follow-ups after venesection. The two patient
groups and rate of expansion of aneurysms with
elevated homocysteine were compared with those
with normal levels using the Mann-Whitney U test.
Rapid expanders were compared with slow
expanders across a range of independent factors that
we hypothesized may be associated with rates of
expansion. These factors were age (in 5-year strata),
initial aortic diameter, smoking status (categorized
into lifelong nonsmokers, ex-smokers, and current
smokers), hypertension (treatment for and measured),
presence of hypercholesterolaemia, history of coro-
nary heart disease or stroke, presence of peripheral ar-
terial disease and level of Hcy. All these factors were
initially included in a multivariate logistic regression,
with the use of SPSS software.
At the beginning of the study 10 subjects were se-
lected at random for assessment of intra-observer
and inter-observer agreement of aortic diameter mea-
surements. Each patient was scanned three times by
each operator as well as by a senior vascular sonogra-
pher. All scans were performed with the operators
blinded to previous aortic diameter measurements.
Nonparametric tests and SPSS software were used to
compare mean intra-observer and inter-observer dif-
ferences in aortic diameter measurements. No signifi-
cant differences were found between observers, with
95% of differences in each of anteroposterior and
transverse diameters being <3 mm.
Results
Over the study period, 202 patients were under
surveillance at the vascular unit. Of these 108 were
included in this study and 94 were excluded. Twenty
393Hyperhomocysteinaemia is Associated with the Rate of AAA Expansiontwo patients were excluded due to lack of 2 ultrasound
scan results, sixty two patients did not have homocys-
teine levels tested at the time of the study, six had renal
failure prior to Hcy testing, and four patients did not
have adequate clinical notes available.
A total of 26 women and 82 men were studied.
Mean age was 76.07 (SD 6.93, range 59.51e94.42)
years. The distribution of risk factors among the
patients is summarised in Table 2 with no statistical
difference between the two groups. Mean follow up
time was 19.5 months (range 6e56 months).
Hyperhomocysteinaemia (Hcy 15 mmol/l) was
found in 65 patients (60%) with AAA. There was no
significant difference in size of the AAA at presenta-
tion between the patients with normal Hcy and those
with elevated Hcy (4.1 cm vs. 4.2 cm, Mann-Whitney
U test p¼ 0.28). There was, however, a significant dif-
ference in the rate of expansion of AAA between the
two groups. Median monthly expansion among the
patients with normal Hcy was 0.25 mm/month (range
0e1.5, yearly expansion rate 3 mm/year), whereas
among the Hcy patients, the expansion rate was dou-
ble (0.5 mm/month, yearly expansion rate 6 mm/
year, Mann-Whitney U test p¼ 0.003). More signifi-
cantly 25% of aneurysm patients with an elevated
Hcy had an annual growth rate of >10 mm/year com-
pared to 2% of patients with normal Hcy. There was
no difference in growth rate between AAA <4 cm
and >4 cm in patients with normal Hcy. Patients
with elevated Hcy and aneurysms >4 cm had growth
rates which were double those of patients with nor-
mal HCY (0.6 mm/month vs. 0.3 mm/month, Mann-
Whitney U test p¼ 0.04) (Table 3).
Multivariate analysis of growth rate vs. Hcy, hyper-
tension, smoking and hypercholesterolaemia showed
that Hcy was the sole significant factor affecting
AAA expansion (p¼ 0.004, B¼ 0.03, 95% CI for
B 0.013e0.065). In addition, a significant correlation
between levels of homocysteine and growth rate
Table 2. Summary of risk factors and demographics for patients
with and without hyperhomocysteinaemia
Total Homocysteine
< 15
Homocysteine
 15
No. of Patients 108 43 (40%) 65 (60%)
Males 82 (76%) 52 (80%) 30 (70)%
Mean Age 76.1 6.93 75.4 76.5
Diabetes 15 (14%) 7 (16%) 8 (12%)
Hypertension 60 (54%) 23 (53%) 37 (57%)
Hypercholesterolaemia/
Statin
56 (52%) 24 (56%) 32 (49%)
PVD 29 (27%) 12 (28%) 17 (26%)
IHD 49 (45%) 20 (47%) 29 (45%)
Smokers 34 (31%) 14 (33%) 20 (31%)
CVA 11 (10%) 4 (9%) 7 (11%)using Spearman Rank Correlation (Spearman’s
Rho¼ 0.28, two tailed p¼ 0.003) was found.
Discussion
This analysis confirms reports from other studies that
the rates of expansion of small screenedetected AAA
are low.19,20 The median annual increase in aortic
diameter was 3 mm for patients with normal homo-
cysteine levels, rising to 6.0 mm for patients with
hyperhomocysteinaemia (HyperHcy). For most indi-
vidual patients, these increments are within measure-
ment error for ultrasound scanning.
Inflammation is now considered to be of funda-
mental importance in the pathogenesis of aortic aneu-
rysms. Recent studies have demonstrated that Hcy
induces the synthesis of serine elastase in arterial
sooth muscle cells, causing elastolysis by degradation
of the extracellular matrix and release of elastin pep-
tides chemotactic to smooth muscle cells.21,22 In addi-
tion increased binding and activation of matrix
metalloproteinases 2 and 9 (MMP-2, MMP-9) occurs
in hyperhomocysteinaemia, leading to further
elastin/fibrillar collagen degradation in the tunica
media of AAAs.23,24
Multivariate analysis of the data comparing growth
rate and Hcy, hypertension and high cholesterol
showed that Hcy levels were the sole factor that sig-
nificantly contributed to growth rate (p¼ 0.004). No
independent association with smoking was found,
as has been reported elsewhere.18,25 This may be
due to the relatively small proportion of current
smokers in the study. Hypertension has been docu-
mented as a risk factor for AAA in several studies,
it is surprising, therefore, that hypertension is not
a risk factor for expansion of small aneurysms.26 In
the case of this study, it may be because the majority
of patients with hypertension are adequately treated,
thereby minimizing the impact of this risk factor.
In contrast to previous studies, this work has dem-
onstrated an association between hyperHcy and AAA
expansion.18 The correlation is weak and most likely
to be more complicated than a linear fit. This is to
be expected given the multi-factorial nature of the
condition and the need for further research into the
subject. Median AAA growth rates in hyperHcy
Table 3. Summary of results comparing growth rate and AAA size
Growth Rate
AAA <4 cm
(mm/month)
Growth Rate
AAA 4 cm
(mm/month)
P Value
(Mann-
Whitney)
Hcy< 15 0.25 0.3 0.57
Hcy 15 0.3 (n¼ 23) 0.6 (n¼ 42) 0.04Eur J Vasc Endovasc Surg Vol 33, April 2007
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median growth rates in patients with normal homo-
cysteine levels. The results also showed that a signifi-
cant proportion of patients with hyperHcy (25%) had
rapid growth rates of above 10 mm/year, a rate asso-
ciated with higher risk of rupture. Those with larger
aneurysms (>4 cm) are at greater risk as they were
found to have the highest median growth rate. As
already mentioned, previous studies have shown a
correlation between Hcy levels and AAA size, how-
ever, no previous link has been made between size,
Hcy level and rate of expansion.17
The detection of elevated levels of Hcy in patients
with large, symptomatic, or ruptured AAA is unlikely
to change the treatment of such patients because they
need repair of the AAA. However, it is in the manage-
ment of small (30 to 54 mm in diameter) AAAs that
Hcy levels may have a role. Although surgery is not
indicated for these AAAs, a proportion will expand
until they are large enough to warrant elective inter-
vention before rupture occurs.27 Current practice is
to monitor the diameter of AAAs with periodic ultra-
sound or CT scanning, but our understanding of the
natural history of these aneurysms remains incom-
plete. The identification of risk factor such as Hcy in
this study, that are associated with greater rates of
expansion may help in the planning of surveillance
of AAAs, the identification of high-risk patients who
may benefit from early intervention, and possibly
the development of strategies to prevent expansion.
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